AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, published in the Journal of Surgery (Akpunonu et al., 2025). According to the investigators, Cohealyx demonstrated significantly faster wound bed vascularization and autograft readiness compared to conventional dermal matrices, achieving readiness within 5 to 10 days versus the typical two to four weeks.

Read more at globenewswire.com